Share This Page
Drug Price Trends for NDC 00641-6054
✉ Email this page to a colleague
Average Pharmacy Cost for 00641-6054
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00641-6054
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| MEPERIDINE HCL 100MG/ML INJ | Hikma Pharmaceuticals USA Inc. | 00641-6054-25 | 25X1ML | 59.04 | 2021-08-15 - 2026-08-14 | FSS | |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
00641-6054 Market Analysis and Financial Projection
Market Analysis and Price Projections for Pharmaceutical Drugs: A Comprehensive Overview
Introduction
The pharmaceutical industry is a complex and dynamic sector, influenced by various factors including regulatory changes, technological advancements, and market demand. This article will delve into the current trends, price projections, and key drivers shaping the pharmaceutical market, with a specific focus on the broader context that affects drugs like Meperidine Hydrochloride (NDC: 0641-6054).
Current Market Trends
Drug Price Inflation
The pharmaceutical market is experiencing significant price inflation, particularly driven by specialty pharmaceuticals. According to Vizient, Inc., drug price inflation is projected to grow at 3.8% in the latest Pharmacy Market Outlook, with specialty pharmacy playing a major role[2].
Specialty Pharmaceuticals
Specialty pharmaceuticals, which treat high-cost, complex, or chronic conditions such as cancer, infectious diseases, autoimmune diseases, and pulmonary conditions, are a major contributor to the increase in drug prices. These medications make up the majority of the top 15 medications in spend among Vizient pharmacy program participants. For instance, weight loss drugs like semaglutide and tirzepatide have seen dramatic increases in spending and utilization[2].
Gene Therapies
Gene therapies, another rapidly growing field, involve modifying the expression of genes for therapeutic purposes. These therapies are highly expensive, with some treatments exceeding $2 million per dose. Vizient is tracking over 170 gene and cellular therapies in the pipeline, which are expected to have a significant impact on disease prevention and treatment but also pose challenges such as high costs and complex storage requirements[2].
Price Projections
Overall Market
The average price per unit in the U.S. pharmaceutical market has seen a significant increase. Between 2017 and 2022, the average price per unit in the U.S. rose by 14%, compared to decreases of 9% and 7% in the rest of the world and OECD countries, respectively. This trend indicates that U.S. prices are substantially higher than those in other regions, partly due to a drug mix that skews towards more expensive compounds[4].
Specialty Medications
Specialty medications are expected to see a price increase of 4.18% in the coming year, driven by the approval of novel specialty drugs. In 2023, 42 novel specialty drugs were approved, and 2024 is likely to see a record number of approvals, further driving up costs[2].
Biosimilars and Their Impact
Market Share
Biosimilars, which are biologic products that are highly similar to and have no clinically meaningful differences from an existing FDA-approved reference product, are expected to grow in market share. Despite Humira® still dominating the market, biosimilar adalimumab products are anticipated to gain more market share as pharmacy benefit managers finalize their formulary strategies[2].
Price Stability
Biosimilars are projected to increase in price by only 0.55%, which is significantly lower than the overall price inflation for specialty medications. This stability can help mitigate some of the cost pressures in the pharmaceutical market[2].
Regulatory and Technological Advancements
Evolving Clinical Trial Designs
The biopharma and biotech industries are shifting towards more innovative clinical trial designs to promote efficiency and reduce the exposure of patients to ineffective therapies. This trend is expected to continue in 2025, driven by scientific breakthroughs and technological innovations[3].
Regulatory Landscape
The regulatory landscape is evolving to keep pace with innovation. This includes changes in how clinical trials are conducted, regulated, and approved, which can impact the speed and cost of bringing new drugs to market[3].
Global Pricing Disparities
U.S. vs. International Prices
The U.S. pharmaceutical market is characterized by significantly higher prices compared to other regions. In 2022, the average price per unit in the U.S. was 5.5 times higher than in OECD countries (excluding the U.S.) and 7.7 times higher than in the rest of the world. This disparity is due to both higher prices for the same drugs and a drug mix that favors more expensive compounds[4].
Specific Drug Analysis: Meperidine Hydrochloride (NDC: 0641-6054)
Market Context
Meperidine Hydrochloride, used for preoperative medication, support of anesthesia, and obstetrical analgesia, is part of the broader opioid market. While specific price projections for Meperidine Hydrochloride are not provided in the general market outlook, it is influenced by the overall trends in the pharmaceutical market.
Pricing Factors
The pricing of Meperidine Hydrochloride would be affected by factors such as production costs, regulatory changes, and market demand. Given the current trend of increasing prices in the pharmaceutical sector, it is likely that Meperidine Hydrochloride will also see some level of price increase, although it may not be as steep as that for specialty medications.
Key Takeaways
- Specialty Pharmaceuticals: Driving the highest price increases due to their complex and high-cost nature.
- Gene Therapies: Experiencing rapid growth but posing significant cost and logistical challenges.
- Biosimilars: Expected to increase in market share and offer some price stability.
- Regulatory and Technological Advancements: Shaping the future of clinical trials and drug development.
- Global Pricing Disparities: U.S. prices remain significantly higher than those in other regions.
FAQs
Q: What is driving the increase in drug prices in the U.S.? A: The increase in drug prices in the U.S. is driven by several factors, including the growing utilization of specialty pharmaceuticals, the introduction of new and expensive treatments like gene therapies, and the overall higher prices for drugs in the U.S. compared to other regions[2][4].
Q: How are biosimilars impacting the pharmaceutical market? A: Biosimilars are expected to grow in market share, particularly as pharmacy benefit managers finalize their formulary strategies. They offer a more stable pricing environment compared to the overall market inflation[2].
Q: What are the key trends in clinical trial designs for 2025? A: Clinical trial designs are expected to become more innovative and efficient, shifting away from traditional designs to reduce patient exposure to ineffective therapies and promote faster drug development[3].
Q: Why are gene therapies so expensive? A: Gene therapies are highly expensive due to their complex nature, involving the modification of genes for therapeutic purposes. These treatments often require specialized storage and handling, adding to their cost[2].
Q: How do U.S. drug prices compare to international prices? A: U.S. drug prices are significantly higher than those in other regions. In 2022, the average price per unit in the U.S. was 5.5 times higher than in OECD countries (excluding the U.S.) and 7.7 times higher than in the rest of the world[4].
Sources
- Drug Name and National Drug Code (NDC) Reference Data Instructions - CMS
- Vizient Projects 3.8% Drug Price Increase Driven by Specialty Pharmaceuticals - Vizient, Inc.
- 5 Predictions for the Biopharma and Biotech Industries in 2025 - TFS CRO
- International Market Size and Prices - ASPE
- Label: MEPERIDINE HYDROCHLORIDE injection - DailyMed
More… ↓
